TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33642833

Group type: EXPERIMENTAL
Intervention: GEP-MiNEN
Number of subjects: 46

Group type: COMPARATOR
Intervention: NEC
Number of subjects: 46

Group type: COMPARATOR
Intervention: Poorly differentiated adenocarcinoma
Number of subjects: 46
Study: 32624476

Group type: EXPERIMENTAL
Intervention: Ensemble AI model using combinations of fully connected neural networks with the synthetic minority oversampling technique algorithm
Number of subjects: 1681
Study: 36126736

Group type: EXPERIMENTAL
Intervention: Real respirator
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham respirator
Number of subjects: 128
Study: 32046611

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 12
Study: 35472497

Group type: EXPERIMENTAL
Intervention: 40 mm Hg INP treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: 10 mm Hg INP treatment (sham control)
Number of subjects: 62
Study: 36482694

Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study: 33225810

Group type: EXPERIMENTAL
Intervention: Custom carbon ankle-foot orthosis aligned in more dorsiflexion than clinically provided
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Custom carbon ankle-foot orthosis aligned in more plantarflexion than clinically provided
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (uninjured individuals)
Number of subjects: 24
Study: 36096826

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 1540

Group type: COMPARATOR
Intervention: 4% chlorhexidine
Number of subjects: 1540

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1540
Study: 34273910

Group type: EXPERIMENTAL
Intervention: Empirically-based description
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Basic description
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Emotionally-based description
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Writing arguments for utilizing PE
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Not writing arguments for utilizing PE
Number of subjects: 155
Study: 33714746

Group type: EXPERIMENTAL
Intervention: Nesiritide in addition to standard care
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Placebo in addition to standard care
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Standard care
Number of subjects: 7141
Study: 32955752

Group type: EXPERIMENTAL
Intervention: Adapted Resistance Training with Instability (ARTI), n = 17
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional motor rehabilitation (control), n = 15
Number of subjects: 32
Study: 32955174

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control therapy (physician's choice of enzalutamide or abiraterone plus prednisone)
Number of subjects: 256
Study: 33504345

Group type: EXPERIMENTAL
Intervention: Co-therapy group (DMARDs plus glucocorticoids)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no GC or DMARDs)
Number of subjects: 56
Study: 32034969

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35428281

Group type: EXPERIMENTAL
Intervention: BOOST pACP intervention (four ACP conversation sessions with a trained facilitator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOOST pACP intervention
Number of subjects: 0
Study: 35978272

Group type: EXPERIMENTAL
Intervention: Engager plus usual care
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 280
Study: 33176960

Group type: EXPERIMENTAL
Intervention: Locking plate (group L, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonlocking plate (group N, n = 45)
Number of subjects: 90
Study: 32284175

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current management recommendations for patients with AF and high CHA2DS2-Vasc score
Number of subjects: 0
Study: 34739974

Group type: EXPERIMENTAL
Intervention: Follicular Phase (FP) intervention: quit date set 6-8 days post onset of menses, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard of Care (SC): no menstrual timing of quit date, nicotine replacement therapy transdermal patch for 4 weeks, telephone-based counseling for 6 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (FP and SC)
Number of subjects: 119
Study: 36346534

Group type: EXPERIMENTAL
Intervention: Safinamide (50 mg once daily, increased to 100 mg once daily at day 15)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 32447092

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessed at baseline (executive functions, working memory, premorbid functioning)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cognitive domains related to long-term remission status
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cognitive profile in coexistence with long-term non-remission
Number of subjects: 173
Study: 35123461

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment for 8 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 111
Study: 33059754

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (uninfected subjects)
Number of subjects: 32
Study: 35497697

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine plus midazolam (B/M)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine plus normal saline (B/S)
Number of subjects: 120
Study: 33861440

Group type: COMPARATOR
Intervention: Metformin (500 mg three times daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Curcumin nanomicelles (80 mg/day) + Metformin (500 mg three times daily)
Number of subjects: 100
Study: 36308355

Group type: EXPERIMENTAL
Intervention: Short hydration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional hydration
Number of subjects: 30
Study: 34471483

Group type: EXPERIMENTAL
Intervention: Histopathology diagnosis of EoE
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Symptoms of EoE
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Coexisting conditions
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Esophageal dilatation
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor treatment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Inhalation steroids prescription
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Esophageal radiology
Number of subjects: 111
Study: 36153442

Group type: EXPERIMENTAL
Intervention: Olive pomace oil (OPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-oleic acid sunflower oil (HOSO)
Number of subjects: 0
Study: 34321297

Group type: EXPERIMENTAL
Intervention: PediAppRREST app
Number of subjects: 315

Group type: COMPARATOR
Intervention: CtrlPALS+ (PALS pocket reference card)
Number of subjects: 315

Group type: COMPARATOR
Intervention: CtrlPALS- (no cognitive aid)
Number of subjects: 315
Study: 32185573

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 2-g in 50 mL physiological saline solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 50
Study: 36029105

Group type: EXPERIMENTAL
Intervention: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 80 µg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Recombinant RBD-based protein subunit vaccine (Noora vaccine) 120 µg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33066990

Group type: EXPERIMENTAL
Intervention: 5-degree reverse Trendelenburg (RT) position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Horizontal (H) position
Number of subjects: 60
Study: 33302740

Group type: EXPERIMENTAL
Intervention: 5-min video about fertility (Intervention Group)
Number of subjects: 652

Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 652
Study: 32651812

Group type: EXPERIMENTAL
Intervention: Gas mixture with xenon (25%Xe/30%O2/45%N2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (70%N2/30%O2)
Number of subjects: 14
Study: 32991678

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg/day) for 7 days
Number of subjects: 326

Group type: COMPARATOR
Intervention: SXT (trimethoprim 10 mg/kg/day plus sulfamethoxazole 50 mg/kg/day) for 7 days
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 326

Group type: COMPARATOR
Intervention: SXT
Number of subjects: 326
Study: 32265473

Group type: EXPERIMENTAL
Intervention: MRSA isolates (53 out of 120, 44.2%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MRSA isolates
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MRSA isolates (CC5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CC5 MRSA isolates
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tst-positive MRSA isolates
Number of subjects: 120
Study: 35167583

Group type: EXPERIMENTAL
Intervention: Active PBM combined with intralesional administration of corticoid (IAC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham PBM with intralesional administration of corticoid (IAC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Active PBM combined with IAC
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham PBM with IAC
Number of subjects: 58
Study: 33938690

Group type: EXPERIMENTAL
Intervention: Poly-L-Lactic acid (PLLA) injections combined with subcision
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline injections combined with subcision (control group)
Number of subjects: 31
Study: 33568610

Group type: EXPERIMENTAL
Intervention: Topical curcumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical triamcinolone acetonide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 35033556

Group type: EXPERIMENTAL
Intervention: LCD+INT (Low-Calorie Diet plus Interval Exercise)
Number of subjects: 25

Group type: COMPARATOR
Intervention: LCD (Low-Calorie Diet)
Number of subjects: 25
Study: 35765779

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham Dry Needling (sham DN)
Number of subjects: 60
Study: 34419636

Group type: EXPERIMENTAL
Intervention: Longitudinal extension of uterine incision
Number of subjects: 392

Group type: COMPARATOR
Intervention: Transverse extension of uterine incision
Number of subjects: 392
Study: 34817663

Group type: EXPERIMENTAL
Intervention: Suicide prevention video featuring an adolescent mastering suicidal ideation
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control video unrelated to mental health
Number of subjects: 299
Study: 33765656

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (integrated physical exercise, cognitive training, nutritional advice, and health education lessons) for 12 months
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Number of subjects: 733

Group type: COMPARATOR
Intervention: Conventional health education (control group)
Number of subjects: 733
Study: 32701836

Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg, BID)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 35379559

Group type: COMPARATOR
Intervention: Adherent comparator pharmacies (true control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-adherent comparator pharmacies
Number of subjects: 24
Study: 33667246

Group type: EXPERIMENTAL
Intervention: Google Classroom (GC) integrated with traditional teaching, 1 hour of GC and 1 hour of traditional teaching per week for 15 weeks.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional teaching only, 2 hours per week for 15 weeks.
Number of subjects: 74
Study: 34581239

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour (SB)
Number of subjects: 76
Study: 33373683

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair with remplissage (REMP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Arthroscopic Bankart repair without remplissage (NO REMP)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 35113294

Group type: EXPERIMENTAL
Intervention: Face-to-face, group-based program (OVK)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Computerized, individual program (SPARX)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: OVK and SPARX combined
Number of subjects: 190

Group type: COMPARATOR
Intervention: Monitoring control condition
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 190
Study: 33992687

Group type: EXPERIMENTAL
Intervention: Nitric oxide nasal spray (NONS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline spray (control)
Number of subjects: 80
Study: 34936174

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy Group Intervention targeting Repetitive Negative Thinking (RNT-G)
Number of subjects: 80
Study: 33910614

Group type: EXPERIMENTAL
Intervention: ARBOX (390 mg) administered as 2 capsules per day for 14 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo administered for 14 days
Number of subjects: 140
Study: 70529819

Group type: EXPERIMENTAL
Intervention: Ultrasound guided rectus sheath block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wound infiltration
Number of subjects: 30
Study: 35426602

Group type: EXPERIMENTAL
Intervention: Clinical trial participants with non-paroxysmal AF (non-pAF)
Number of subjects: 5917

Group type: COMPARATOR
Intervention: Real-world patients
Number of subjects: 5917

Group type: EXPERIMENTAL
Intervention: AF type (non-pAF vs. pAF) in clinical trial cohort
Number of subjects: 5917

Group type: EXPERIMENTAL
Intervention: AF type (non-pAF vs. pAF) in real-world cohort
Number of subjects: 5917

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VAS‘c’ score
Number of subjects: 5917
Study: 33131986

Group type: EXPERIMENTAL
Intervention: Digital templates (DT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional resin occlusal splint (CROS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Digital occlusal splint (DOS)
Number of subjects: 61
Study: 35235870

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Localised cancer (Control)
Number of subjects: 1034
Study: 32561489

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure reduction
Number of subjects: 992

Group type: COMPARATOR
Intervention: Standard systolic blood pressure reduction
Number of subjects: 992
Study: 32181609

Group type: EXPERIMENTAL
Intervention: Propulseur universal light (PUL) appliance
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 26
Study: 35809896

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) combined with post-induction chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-GO arm (control)
Number of subjects: 0
Study: 33846728

Group type: EXPERIMENTAL
Intervention: AUT (automatic) annotation protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: MAN (manual) annotation protocol
Number of subjects: 100
Study: 35513159

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 26
Study: 34780478

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus etoposide-platinum (EP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus etoposide-platinum (EP)
Number of subjects: 0
Study: 33502809

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer DES (Firehawk)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Durable polymer DES (XIENCE)
Number of subjects: 1296
Study: 35924803

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 μg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.0 μg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study: 35640116

Group type: EXPERIMENTAL
Intervention: Diet intervention (hypocaloric diet of 1000-1500 kcal/day and high protein meal replacements)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 34016293

Group type: EXPERIMENTAL
Intervention: 2-session marijuana check-up (MCU) intervention
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 6-session marijuana check-up (MCU) intervention
Number of subjects: 186
Study: 33270739

Group type: EXPERIMENTAL
Intervention: Lumbar spine imaging (radiography, CT, MRI)
Number of subjects: 13458

Group type: EXPERIMENTAL
Intervention: Radiography
Number of subjects: 13458

Group type: EXPERIMENTAL
Intervention: CT and MRI
Number of subjects: 13458

Group type: EXPERIMENTAL
Intervention: Self-reported back pain
Number of subjects: 13458

Group type: EXPERIMENTAL
Intervention: Estimated costs for lumbar spine imaging
Number of subjects: 13458
Study: 33625162

Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Senna glycoside
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 107
Study: 32370774

Group type: EXPERIMENTAL
Intervention: Pillbox-enabled self-administered therapy (SAT) with HRZE fixed-dose combination therapy for 15 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard directly observed therapy (DOT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pillbox-enabled self-administered therapy (SAT)
Number of subjects: 144
Study: 35363330

Group type: EXPERIMENTAL
Intervention: SRP + PDT (test group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 60
Study: 33021443

Group type: EXPERIMENTAL
Intervention: Scrotal orchidopexy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Inguinal orchidopexy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 161
Study: 32680556

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cancer recovery (MBCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tai chi/Qigong (TCQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 0
Study: 35037275

Group type: EXPERIMENTAL
Intervention: Male Athlete Body Project (MABP)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 79
Study: 34572743

Group type: EXPERIMENTAL
Intervention: HTP-CT
Number of subjects: 33

Group type: COMPARATOR
Intervention: CT
Number of subjects: 33
Study: 32795544

Group type: EXPERIMENTAL
Intervention: Dronabinol therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cannabis use
Number of subjects: 91
Study: 36207867

Group type: EXPERIMENTAL
Intervention: Gap Balancing (GB) technique
Number of subjects: 57

Group type: COMPARATOR
Intervention: Measured Resection (MR) technique
Number of subjects: 57
Study: 34161982

Group type: EXPERIMENTAL
Intervention: Patients' strategies to address physical problems after hospitalization.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients' strategies to address cognitive problems after hospitalization.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients' strategies to address emotional problems after hospitalization.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Social support and previous familiarity with the health care system.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Persistent problems after ARDS.
Number of subjects: 46
Study: 32302671

Group type: EXPERIMENTAL
Intervention: Mother and Child Education Program (MOECP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35881907

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg before PCI and 0.5 mg daily after until discharge)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 451
Study: 34039352

Group type: EXPERIMENTAL
Intervention: Adjuvant HIPEC
Number of subjects: 0
Study: 35403395

Group type: EXPERIMENTAL
Intervention: Comprehensive group (simultaneous electroacupuncture at antagonistic and agonistic muscles)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antagonistic muscle group (simple electroacupuncture at antagonistic muscle)
Number of subjects: 60
Study: 33452200

Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio guided treatment of non-culprit lesions during the index procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred cardiac MR-guided management within 4 days to 6 weeks
Number of subjects: 0
Study: 32871917

Group type: EXPERIMENTAL
Intervention: Adductor canal block combined with local infiltration analgesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Adductor canal block alone
Number of subjects: 72
Study: 36150665

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham taVNS
Number of subjects: 52
Study: 32029493

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36494834

Group type: EXPERIMENTAL
Intervention: focal HDR brachytherapy boost (fBT) of 13–15 Gy in 1 fraction followed by stereotactic radiotherapy (sRT) 36.25‐40 Gy in 5 fractions
Number of subjects: 150

Group type: COMPARATOR
Intervention: standard-of-care (SOC) high dose rate (HDR) brachytherapy boost to radiotherapy (RT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: focal HDR brachytherapy boost (fBT)
Number of subjects: 150
Study: 34412658

Group type: EXPERIMENTAL
Intervention: Digital healthcare system rehabilitation (intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brochure-based rehabilitation (control)
Number of subjects: 100
Study: 33788485

Group type: EXPERIMENTAL
Intervention: Thumbtack needling therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined treatment (thumbtack needling + external treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: External treatment (shangshi zhitong plaster)
Number of subjects: 120
Study: 35648044

Group type: EXPERIMENTAL
Intervention: Kikyo-to (Kt) 2500 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (lactose) 2500 mg
Number of subjects: 70